Item 2.01. COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS.
As previously disclosed in the Current Report on Form 8-K filed by
As a result of the Merger, on the Closing Date, Hillrom, through its wholly owned subsidiary, acquired all of the assets comprising Bardy's business of the design, development, manufacture, production, assembly, marketing, promotion, distribution, sale, clinical use and other commercialization activities involving certain currently-marketed and in-development cardiac digital health, diagnostic, data management and remote patient monitoring devices, technologies and services.
Pursuant to the terms of the Merger Agreement, on the Closing Date, holders of
outstanding shares of Bardy common and preferred stock and holders of Bardy
warrants, stock options and other equity-related awards (collectively, the
"Holders") received cash in the amount of approximately
The foregoing description of the Merger Agreement does not purport to be
complete and is qualified in its entirety by reference to the actual terms of
the Merger Agreement, a copy of which was filed as Exhibit 2.1 to Hillrom's
Current Report on Form 8-K filed on
Hillrom has determined that it is not required to file separate financial statements of Bardy under Rule 3-05 of Regulation S-X or pro forma financial information relating to the acquisition of Bardy under Article 11 of Regulation S-X.
Item 9.01.FINANCIAL STATEMENTS AND EXHIBITS.
(d)Exhibits. 2.1 Agreement and Plan of Merger dated as ofJanuary 15, 2021 by and amongHill-Rom, Inc. , Barcelona Merger Sub,Bardy Diagnostics, Inc. andFortis Advisors LLC (incorporated herein by reference to Exhibit 2.1 to Hillrom's Form 8-K filed onJanuary 19, 2021 ) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
--------------------------------------------------------------------------------
© Edgar Online, source